ALTEOGEN Inc. (KOSDAQ: 196170)

Market Cap	18.47T
Revenue (ttm)	90.79B
Net Income (ttm)	-1.28B
Shares Out	53.30M
EPS (ttm)	-24.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,636,616
Open	344,000
Previous Close	350,500
Day's Range	279,000 - 346,500
52-Week Range	66,100 - 455,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 145
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196170

Financial Performance

In 2023, ALTEOGEN's revenue was 96.52 billion, an increase of 235.08% compared to the previous year's 28.81 billion. Losses were -3.37 billion, -58.61% less than in 2022.